General News Regulated OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN September 30, 2021
General News Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN January 20, 2021
General News Regulated OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices EN November 9, 2020
General News Regulated Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer EN October 13, 2020
General News Regulated Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 9, 2020
General News Regulated Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 5, 2020
General News Regulated Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME EN January 7, 2020
General News Regulated Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME EN December 19, 2019
General News Regulated Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME EN September 9, 2019
General News Regulated Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME EN August 20, 2019
News Regulated Transparency/Denominator Regulated information – Transparency Statement OXUR shares EN NL May 10, 2019
News Regulated Transparency/Denominator Regulated information – Transparency Statement Clay EN NL May 10, 2019
